Table 1.

Previous T-VEC trials in melanoma

Phase	N	Disease	Stage	Intervention	Primary endpoint	NCT
III	660	Melanoma	IIIB–IV	T-VEC + pembrolizumab vs placebo + pembrolizumab	PFS, OS	NCT02263508
II	–	Melanoma	Resectable IIIB–IVM1a	Neoadjuvant T-VEC vs surgery alone	RFS	NCT02211131
II	–	Melanoma and others	IIIB–IV	T-VEC with or without radiation	Response	NCT02819843
III	–	Melanoma	IIIB–IVM1a	T-VEC vs PV-10 vs chemotherapy	PFS	NCT02288897
I	–	Melanoma and others	IVM1c	Visceral intrahepatic metastases injection	Safety	NCT02509507
II	–	Melanoma	IIIB–IV	T-VEC	Detection of T-VEC DNA in blood or urine	NCT02014441
II	–	Melanoma	IIIB–IV	T-VEC	Correlation of intratumoral CD8+ cells and ORR	NCT02366195

Abbreviations: T-VEC, talimogene laherparepvec; PFS, progression-free survival; OS, overall survival; RFS, recurrence-free survival; ORR, overall response rate.